AKRO | Akero Therapeutics, Inc. | [NASD]
Index- P/E- EPS (ttm)-2.74 Insider Own2.10% Shs Outstand46.94M Perf Week-1.89%
Market Cap2.42B Forward P/E- EPS next Y-3.31 Insider Trans-54.22% Shs Float42.37M Perf Month2.54%
Income-111.80M PEG- EPS next Q-0.62 Inst Own108.40% Short Float / Ratio10.97% / 6.95 Perf Quarter1.84%
Sales- P/S- EPS this Y0.70% Inst Trans20.36% Short Interest4.65M Perf Half Y-1.43%
Book/sh6.53 P/B6.85 EPS next Y-20.40% ROA-35.20% Target Price59.14 Perf Year446.94%
Cash/sh6.33 P/C7.06 EPS next 5Y-14.60% ROE-39.80% 52W Range7.52 - 54.88 Perf YTD-18.36%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-18.48% Beta-0.92
Dividend %- Quick Ratio20.80 Sales past 5Y- Gross Margin- 52W Low494.95% ATR2.17
Employees41 Current Ratio20.80 Sales Q/Q- Oper. Margin- RSI (14)50.63 Volatility5.25% 4.92%
OptionableYes Debt/Eq0.08 EPS Q/Q26.00% Profit Margin- Rel Volume0.50 Prev Close43.81
ShortableYes LT Debt/Eq0.08 Earnings- Payout- Avg Volume668.94K Price44.74
Recom1.70 SMA20-1.92% SMA506.32% SMA20015.04% Volume333,329 Change2.12%
Date Action Analyst Rating Change Price Target Change
Jan-27-23Upgrade Morgan Stanley Equal-Weight → Overweight $40 → $65
Sep-14-22Upgrade Evercore ISI In-line → Outperform $10 → $50
Oct-19-21Downgrade Morgan Stanley Overweight → Equal-Weight $27
Sep-10-21Initiated BofA Securities Buy $40
Feb-26-21Initiated Guggenheim Buy $54
Sep-10-20Initiated Morgan Stanley Overweight $70
Jul-20-20Reiterated H.C. Wainwright Buy $45 → $62
Jul-07-20Initiated Chardan Capital Markets Buy $79
Jul-01-20Reiterated H.C. Wainwright Buy $33 → $45
Mar-02-20Initiated H.C. Wainwright Buy $33
Jul-15-19Initiated Evercore ISI Outperform $35
May-26-23 10:51AM
May-24-23 08:14AM
May-23-23 09:55AM
May-17-23 01:59PM
May-16-23 06:53PM
06:33AM Loading…
06:33AM
May-15-23 07:00AM
May-10-23 08:50AM
May-04-23 09:21AM
06:26AM
Apr-18-23 09:55AM
Mar-29-23 04:01PM
Mar-22-23 04:09PM
09:14AM
Mar-17-23 07:00AM
08:00AM Loading…
Jan-10-23 08:00AM
Jan-04-23 08:00AM
Dec-22-22 07:44AM
Dec-21-22 04:01PM
Dec-20-22 11:15AM
Dec-08-22 07:00AM
Nov-13-22 07:46AM
Nov-10-22 04:05PM
Nov-07-22 09:40AM
07:30AM
Nov-04-22 07:00AM
Nov-03-22 06:53PM
Nov-02-22 11:14AM
Oct-21-22 12:27PM
12:06PM
09:40AM Loading…
09:40AM
Oct-11-22 08:56PM
04:01PM
Oct-05-22 09:40AM
Sep-23-22 06:35PM
Sep-19-22 04:01PM
Sep-14-22 08:07PM
04:35PM
02:50PM
01:35PM
10:27AM
Sep-13-22 04:31PM
04:01PM
11:05AM
11:04AM
09:10AM
08:27AM
07:49AM
06:00AM
Sep-08-22 04:01PM
Aug-25-22 11:53AM
Aug-24-22 10:28AM
08:00AM
Aug-04-22 04:05PM
Jun-27-22 07:00AM
Jun-16-22 09:22AM
07:00AM
Jun-13-22 08:00AM
Jun-01-22 04:05PM
May-06-22 07:00AM
May-02-22 07:30AM
Mar-07-22 04:13AM
Feb-25-22 07:00AM
Feb-08-22 08:00AM
Jan-14-22 09:40AM
Jan-04-22 04:05PM
Nov-26-21 05:28PM
Nov-17-21 10:07AM
Nov-12-21 08:01AM
07:00AM
Nov-09-21 04:15PM
Oct-20-21 10:03AM
Oct-19-21 04:15PM
Oct-05-21 08:00AM
Sep-08-21 06:21AM
Sep-07-21 08:00AM
Aug-13-21 07:00AM
Jul-14-21 08:00AM
Jul-08-21 01:24PM
11:10AM
Jun-25-21 11:30AM
Jun-21-21 11:33AM
08:00AM
Jun-09-21 10:03AM
09:06AM
Jun-01-21 08:00AM
May-28-21 04:05PM
10:09AM
May-13-21 07:00AM
Apr-26-21 08:00AM
Mar-23-21 08:00AM
Mar-22-21 04:01PM
06:30AM
Mar-16-21 08:00AM
Mar-11-21 11:40PM
Feb-24-21 08:30AM
Feb-23-21 04:05PM
Jan-04-21 04:05PM
Dec-12-20 10:07PM
Nov-24-20 04:05PM
Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company is also conducting a Phase 2b clinical trial to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Graham G. WalmsleyDirectorSep 19Buy26.00400,00010,400,000400,000May 23 09:55 PM
Graham G. WalmsleyDirectorMay 19Buy42.00120,0005,040,000520,000May 23 09:55 PM
Cheng AndrewPresident & CEOMay 01Option Exercise0.6125,00015,375434,293May 03 08:28 PM
Cheng AndrewPresident & CEOMay 01Sale45.0725,0001,126,860409,293May 03 08:28 PM
Cheng AndrewPresident & CEOApr 18Option Exercise0.6140,00024,600409,293May 03 08:28 PM
Cheng AndrewPresident & CEOApr 03Option Exercise0.6125,00015,375394,293Apr 05 04:55 PM
Cheng AndrewPresident & CEOApr 03Sale37.9425,000948,576369,293Apr 05 04:55 PM
Cheng AndrewPresident & CEOMar 01Option Exercise0.6125,00015,375395,999Mar 03 04:21 PM
Cheng AndrewPresident & CEOMar 01Sale46.6525,0001,166,338370,999Mar 03 04:21 PM
Cheng AndrewPresident & CEOFeb 01Option Exercise0.6125,00015,375395,999Feb 03 05:25 PM
Cheng AndrewPresident & CEOFeb 01Sale49.0625,0001,226,395370,999Feb 03 05:25 PM
Yale CatrionaChief Development OfficerJan 13Sale50.535,000252,65181,268Jan 18 05:30 PM
Cheng AndrewPresident & CEOJan 03Option Exercise0.6125,00015,375395,999Jan 05 06:46 PM
Young JonathanChief Operating OfficerJan 03Option Exercise0.618,7775,398193,688Jan 05 05:56 PM
Cheng AndrewPresident & CEOJan 03Sale51.2725,0001,281,751370,999Jan 05 06:46 PM
Young JonathanChief Operating OfficerJan 03Sale54.648,777479,560184,911Jan 05 05:56 PM
Rolph TimothyChief Scientific OfficerDec 29Option Exercise28.357,816221,584210,848Dec 30 04:26 PM
Rolph TimothyChief Scientific OfficerDec 29Sale51.0520,3161,037,119190,532Dec 30 04:26 PM
Rolph TimothyChief Scientific OfficerDec 28Option Exercise28.351,70048,195204,732Dec 30 04:26 PM
White William RichardChief Financial OfficerDec 28Option Exercise7.019997,00224,623Dec 29 05:41 PM
Rolph TimothyChief Scientific OfficerDec 28Sale50.001,70085,006203,032Dec 30 04:26 PM
White William RichardChief Financial OfficerDec 28Sale49.7699949,71423,624Dec 29 05:41 PM
White William RichardChief Financial OfficerDec 27Option Exercise7.0119,001133,17842,625Dec 29 05:41 PM
Young JonathanChief Operating OfficerDec 27Option Exercise6.0312,50075,352194,949Dec 28 06:30 PM
White William RichardChief Financial OfficerDec 27Sale49.7719,001945,60923,624Dec 29 05:41 PM
Young JonathanChief Operating OfficerDec 27Sale49.5712,500619,609182,449Dec 28 06:30 PM
Cheng AndrewPresident & CEODec 16Option Exercise0.618,5005,228370,999Dec 20 07:46 PM
Yale CatrionaChief Development OfficerDec 12Sale43.235,000216,13786,268Dec 13 08:24 PM
Cheng AndrewPresident & CEODec 01Option Exercise0.6110,0006,150320,148Dec 02 05:52 PM
Skorpios TrustFormer 10% ownerDec 01Sale43.501,636,00071,166,0003,271,829Dec 05 04:36 PM
Cheng AndrewPresident & CEODec 01Sale46.0710,000460,700310,148Dec 02 05:52 PM
Harrison Seth LoringDirectorNov 30Sale46.9412,030564,673148,063Dec 02 05:48 PM
Harrison Seth LoringDirectorNov 30Sale46.9411,101521,067136,301Dec 02 05:48 PM
Rolph TimothyChief Scientific OfficerNov 16Sale45.473,947179,464183,837Nov 16 07:15 PM
Rolph TimothyChief Scientific OfficerNov 15Sale45.043,138141,343187,784Nov 16 07:15 PM
Yale CatrionaChief Development OfficerNov 10Sale39.425,000197,10572,073Nov 14 05:26 PM
Cheng AndrewPresident & CEONov 01Option Exercise0.6110,0006,150320,148Nov 02 09:52 PM
Cheng AndrewPresident & CEONov 01Sale43.4210,000434,183310,148Nov 02 09:52 PM
Harrison Seth LoringDirectorOct 28Sale40.3122,965925,738160,093Nov 01 05:38 PM
Harrison Seth LoringDirectorOct 28Sale40.3121,138852,091147,402Nov 01 05:38 PM
Harrison Seth LoringDirectorOct 27Sale41.5372,1722,997,575183,058Oct 27 09:50 PM
Harrison Seth LoringDirectorOct 27Sale41.5366,4262,758,920168,540Oct 27 09:50 PM
Harrison Seth LoringDirectorOct 26Sale43.7571,5833,131,402255,230Oct 27 09:50 PM
Harrison Seth LoringDirectorOct 26Sale43.7565,8852,882,142234,966Oct 27 09:50 PM
Rolph TimothyChief Scientific OfficerOct 26Sale45.034,762214,433190,922Oct 27 09:27 PM
Rolph TimothyChief Scientific OfficerOct 25Option Exercise10.3110,000103,116206,337Oct 27 09:27 PM
Young JonathanChief Operating OfficerOct 25Option Exercise6.3612,50079,500175,754Oct 27 09:25 PM
Young JonathanChief Operating OfficerOct 25Sale44.7212,500558,944163,254Oct 27 09:25 PM
Rolph TimothyChief Scientific OfficerOct 25Sale45.0910,653480,349195,684Oct 27 09:27 PM
Harrison Seth LoringDirectorOct 25Sale44.924,906220,359326,813Oct 27 09:50 PM
Harrison Seth LoringDirectorOct 25Sale44.924,515202,797300,851Oct 27 09:50 PM
White William RichardChief Financial OfficerOct 13Option Exercise7.0120,000140,18024,429Oct 17 05:40 PM
White William RichardChief Financial OfficerOct 13Sale39.8220,000796,4004,429Oct 17 05:40 PM
Yale CatrionaChief Development OfficerOct 10Sale37.995,000189,95077,073Oct 12 04:59 PM
Rolph TimothyChief Scientific OfficerOct 06Option Exercise21.0910,000210,900208,837Oct 07 06:00 PM
Rolph TimothyChief Scientific OfficerOct 06Sale39.2922,500884,025186,337Oct 07 06:00 PM
Cheng AndrewPresident & CEOOct 03Option Exercise0.6110,0006,150320,148Oct 05 08:55 AM
Cheng AndrewPresident & CEOOct 03Sale33.2310,000332,278310,148Oct 05 08:55 AM
Rolph TimothyChief Scientific OfficerSep 30Option Exercise16.4320,000328,589243,837Oct 04 08:57 PM
Rolph TimothyChief Scientific OfficerSep 30Sale32.7245,0001,472,400198,837Oct 04 08:57 PM
White William RichardChief Financial OfficerSep 13Option Exercise7.0132,500227,79236,929Sep 15 07:57 PM
Cheng AndrewPresident & CEOSep 13Option Exercise0.6160,00036,900370,148Sep 15 07:59 PM
Cheng AndrewPresident & CEOSep 13Sale27.4260,0001,645,444310,148Sep 15 07:59 PM
Yale CatrionaChief Development OfficerSep 13Sale27.4840,0001,099,22882,073Sep 15 07:59 PM
White William RichardChief Financial OfficerSep 13Sale27.0332,500878,3414,429Sep 15 07:57 PM
Rolph TimothyChief Scientific OfficerSep 13Sale29.1822,500656,550223,837Sep 15 07:56 PM